Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study-Reference-Cited by-同舟云学术

Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study

Published:2020-10-09 Issue:5 Volume:184 Page:857-870
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Cork M.J.¹²,Thaçi D.³,Eichenfield L.F.⁴,Arkwright P.D.⁵^ORCID,Sun X.⁶,Chen Z.⁷,Akinlade B.⁷^ORCID,Boklage S.⁷,Guillemin I.⁸,Kosloski M.P.⁷,Kamal M.A.⁷,O’Malley J.T.⁹,Patel N.⁹,Graham N.M.H.⁷,Bansal A.⁷^ORCID

Affiliation:

1. Sheffield Dermatology Research Department of Infection Immunity & Cardiovascular Disease University of Sheffield Sheffield UK

2. Sheffield Children’s Hospital Clinical Research Facility Sheffield UK

3. Institute and Comprehensive Center of Inflammation Medicine University of Lübeck Lübeck Germany

4. Departments of Dermatology University of California San Diego School of Medicine San Diego CA USA

5. Lydia Becker Institute of Immunology and Inflammation University of Manchester Manchester UK

6. Regeneron Pharmaceuticals, Inc. Basking RidgeNJ USA

7. Regeneron Pharmaceuticals, Inc. TarrytownNY USA

8. Sanofi Chilly Mazarin France

9. Sanofi CambridgeMA USA

Funder

Sanofi

Regeneron Pharmaceuticals

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.19460

Reference28 articles.

1. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma☆

2. SilverbergJI BarbarotS GadkariAet al.Epidemiology of atopic dermatitis (AD) in children aged 6–11 years: a cross‐sectional study in the United States (US) Canada Europe and Japan. Presented at the78th Annual Meeting of the American Academy of Dermatology Denver CO USA 20–24 March 2020.

3. Quality of Life and Disease Severity Are Correlated in Patients with Atopic Dermatitis

4. Atopic Dermatitis

5. Financial burden of emergency department visits for atopic dermatitis in the United States

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. De l’asthme difficile à traiter à l’asthme sévère : palier 5;Revue des Maladies Respiratoires;2024-08

2. Use of Dupilumab in Pediatric Patients: A Review;Current Pediatrics Reports;2024-06-20

3. [Artículo traducido] Eficacia a medio plazo de dupilumab en niños de ≥ 36 meses a < 12 años con dermatitis atópica: serie de casos;Actas Dermo-Sifiliográficas;2024-06

4. Mid-Term Efficacy of Dupilumab in Children Aged ≥ 36 Months to <12 Years With Atopic Dermatitis: A Case Series;Actas Dermo-Sifiliográficas;2024-06

5. Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review;Frontiers in Immunology;2024-05-15